Boehringer Ingelheim Vetmedica Gmbh

Other

Philip Utley

Jeremy Kroll

Eric Martin Vaughn

Michael B Roof

Francois-Xavier Orveillon

Michael Dennis Piontkowski

Volker Ohlinger

Stefan Pesch

Kim Burgard

Sarah M Layton

Troy James Kaiser

Scott Eugene Bucklin

Dianna Murphy Jordan

The present invention relates to a porcine parvovirus (PPV) viral protein 2 (VP2) having at amino acid position 228 a glutamic acid residue or a glutamate residue, and/or at amino acid position 414 a serine residue, and/or at amino acid position 419 a glutamine residue, and/or at amino acid position 436 a threonine residue. Further, the present invention relates to immunogenic compositions comprising said PPV viral protein 2 (VP2). Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by PPV infection in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

Vaccine against porcine parvovirus

The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.

European PRRSV strain

The invention provides immunogenic compositions useful for inhibiting, treating, protecting, or preventing infection by. These immunogenic compositions are demonstrated to usefully stimulate immunogenic responses in treated pigs. Some vaccines stimulated reactions sufficient to be protective against. In addition, the invention provides kits comprising the immunogenic compositions; as well as, methods of using the compositions and kits.

[object Object]

Growing community of inventors

Slater, IA, United States of America

Philip Utley